Amendment No. 1 to the Territory B Alliance Support Agreement



 Exhibit 10.7 
 * CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED 
 SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION 
 EXECUTION COPY 
 Amendment No. 1 
 to the Territory B 
 Alliance Support Agreement 
 This AMENDMENT No. 1 (this
“Amendment No. 1”), dated as of October 17, 2001 and effective as of October 1, 2001 (the “Effective Date”) to the Territory B Alliance Support Agreement dated as of January 1, 1997 is hereby
made by and between Sanofi-Synthélabo, a société anonyme organized and existing under the laws of the French Republic (“SSBO”) as the successor in interest to Sanofi, a
société anonyme organized under the laws of the French Republic, and Bristol-Myers Squibb Company, a Delaware corporation (“BMS” and, together with SSBO, the “Parties” and,
individually, each a “Party”). 
 W I T N E S S E T H:

 WHEREAS, the Parties have entered into a Territory B Alliance Support Agreement dated as of January 1, 1997, as formerly amended or
modified (the “Agreement”); and 
 WHEREAS, the Parties wish to amend the non-competition provisions of the Agreement with
respect to the commercialization of Irbesartan Products or any other product having substantially the same mechanism of action. 
 NOW
THEREFORE, in consideration of the foregoing premises and the mutual covenants and the terms and conditions set forth herein, the Parties hereby agree as follows: 
 1. Capitalized terms used but not otherwise defined herein shall have the meanings given to such terms in the Agreement. 
  

	2.	(a) Article I of the Agreement shall be amended by the addition of the following defined terms to Section 1.01: 

 “Alliance Support Agreements” means this Agreement, the Territory A Alliance Support Agreement dated as of
January 1, 1997 by and between each of the Parties and the U.S. Alliance Support Agreement dated as of October 17, 2001 by and between each of the Parties, in each case as amended, modified, supplemented or restated from time to time.

 “Business” means the commercialization, directly or indirectly, of any Irbesartan Product or any other
product having substantially the same mechanism of action as any Irbesartan Product (including, without limitation, through the granting of a license to any intellectual property related to Irbesartan or Irbesartan Products). 
 “Compliance Period” means the period commencing on the Effective Date and ending upon [*] of the date on which the [*]
Alliance Support Agreements expires or terminates. 
 “Corresponding Percentage” means (i) 50.1% if the
Non-Acquisition Party is BMS, and (ii) 49.9% if the Non-Acquisition Party is SSBO. 

  


 * CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 








 “SSBO” means Sanofi-Synthélabo, a
société anonyme organized and existing under the laws of the French Republic and the successor in interest to Sanofi. 
 (b) Article I of the Agreement shall be further amended by the addition of the following defined terms to Section 1.02: 
  

			
	 Defined Term
	  	Section Where Defined
	 Acquisition Party
	  	9.02
	 Competing Business
	  	     9.02(a)
	 Competitive Activities
	  	9.01
	 Covered Enterprise
	  	9.01
	 Non-Acquisition Party
	  	9.02

 3. Section 5.02 of the Agreement shall be amended by deleting Section 5.02 in its entirety and replacing
it with the following paragraph: 
 Section 5.02 Non-Competition. (a) During the period from and after the date hereof until
[*], each Party shall not, and shall cause its Affiliates not to, directly or indirectly, except through the Territory B Partnership, [*]. 
 (b) Notwithstanding anything to the contrary contained herein, the restrictions of Section 5.02(a) hereof shall not apply (i) with respect only to any terminated country(ies), to the highest offeror (and its
Affiliates) under Section 7.03(i) hereof; (ii) with respect only to any terminated country(ies), to the Country Non-Terminating Party (and its Affiliates) which proceeds alone with the commercialization of any Clopidogrel Product in such
country(ies) pursuant to Section 7.03(ii) hereof; (iii) with respect only to any Clopidogrel Product subject to an Unsatisfactory Final Outcome, to the highest offeror (and its Affiliates) under Section 7.05(a)(iii) hereof;
(iv) with respect only to any Clopidogrel Product subject to a Safety Problem, to the Non-Concerned Party (and its Affiliates) which continues commercializing such Clopidogrel Product in accordance with Section 7.05(b)(ii) hereof;
(v) following expiration or early termination of this Agreement, to the highest offeror (and its Affiliates) under Section 7.07(iii) hereof; and (vi) upon payment of the Non-Renewal Valuation following exercise of the special put
option under Section 7.08 hereof, to SSBO and its Affiliates. 
 4. Section 7.01(c) of the Agreement shall be amended by deleting the last sentence
thereof and replacing it with the following sentence: 
 All of the Parties’ rights and obligations under this Article VII and under
Sections 5.02, 5.03, 5.06, 6.01, 6.02, 6.03, 8.02, 8.03, 8.04 and 8.12 and Article IX shall survive such expiration or early termination for the applicable period, if any. 
  


 
 2
 
  


 * CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 








 5. The Agreement shall be amended by the addition of the following Article IX: 
 ARTICLE IX 
 NON-COMPETITION 
 Section 9.01 Non-Competition Covenants. Each Party agrees not to, and to cause each of its Affiliates not to, directly or indirectly (other
than to or through its direct or indirect participation in the Territory B Partnership), at any time during the Compliance Period, engage in or undertake any Competitive Activities anywhere within Territory B. “Competitive
Activities” shall mean (i) [*], or (ii) [*] (each such Person, a “Covered Enterprise”). 
 Section 9.02 Acquisition of Ownership Interest in a Covered Enterprise. Section 9.01 hereof shall in no event be deemed to prevent or restrict or apply to the acquisition by a Party or its Affiliates (the
“Acquisition Party”, with the remaining Party being the “Non-Acquisition Party”) of an ownership interest (regardless of whether such interest is a minority interest, a majority interest or a controlling interest)
in a Covered Enterprise and/or to the exercise of corresponding operational, management or control rights with respect to such Covered Enterprise, except that if at any time following the first anniversary of the acquisition by the Acquisition Party
of ownership interests representing in the aggregate more than [*] of the total equity in a Covered Enterprise the Non-Acquisition Party demonstrates to the Acquisition Party that such acquisition has had a material adverse effect on the
commercialization of Irbesartan Products by the Territory B Partnership in the portion of Territory B where such Covered Enterprise engages in or undertakes the Business, the Acquisition Party shall, at its option, either: 
 (a) cause the Covered Enterprise to divest itself of the Business (the “Competing Business”) within twelve (12) months of such
demonstration by the Non-Acquisition Party; or 
 (b) offer to the Non-Acquisition Party the right to acquire the Corresponding Percentage of
the Acquisition Party’s ownership interest in the Competing Business at a valuation which, taking into account the percentage of the gross annual revenues of the Covered Enterprise that are represented by the Competing Business, is in
proportion to the price paid by the Acquisition Party for the Covered Enterprise, in the understanding that should the Non-Acquisition Party decline to acquire such a participation in the Competing Business the Non-Acquisition Party shall have no
further rights under this Article IX to challenge such acquisition. 
 Section 9.03 Exceptions to Non-Competition Covenants.
Sections 9.01 and 9.02 hereof shall not prevent or restrict or apply to: 
 (a) A Party that elects to proceed alone with the
commercialization of Irbesartan Products in any country within Territory B or in all of Territory B pursuant to: 
  

 
 3
 
  


 * CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 








 (i) Section 7.03(ii) hereof, but solely with respect to such Party’s (or its Affiliates’)
Competitive Activities in the countries in Territory B where such Party has elected to proceed alone; or 
 (ii) Section 7.05(b)(ii)
hereof; 
 in the understanding that the other Party shall remain subject to Sections 9.01 and 9.02 hereof in any such countries and in the remaining
countries in Territory B. 
 (b) A Party that acquires the right to commercialize Irbesartan Products in any country within Territory B or in
all of Territory B from the Territory B Partnership (and/or the other Party and its Affiliates) pursuant to: 
 (i) Section 7.03(i)
hereof, but solely with respect to such Party’s (or its Affiliates’) Competitive Activities in the countries in Territory B with respect to which such rights were acquired; 
 (ii) Section 7.05(a)(iii) hereof; 
 (iii)
Section 7.07(iii) hereof; or 
 (iv) Section 7.08 hereof; 
 in the understanding that the other Party shall remain subject to Sections 9.01 and 9.02 hereof in any such countries and in the remaining countries in Territory B. 
 (c) Either Party after the date on which a Third Party acquires the right to commercialize Irbesartan Products in any country within Territory B or in
all of Territory B from the Territory B Partnership (and/or the Parties and their Affiliates) pursuant to: 
 (i) Section 7.03(i) hereof,
but solely with respect to the Competitive Activities of the Parties or their Affiliates in the countries in Territory B with respect to which such rights were acquired; 
 (ii) Section 7.05(a)(iii) hereof; or 
 (iii) Section 7.07(iii) hereof. 
 Section 9.04 Survival. The expiration or early termination of this Agreement pursuant to Article VII hereof expressly shall not relieve any
Party from its obligations under this Article IX, which Article shall survive until the end of the Compliance Period. 
 Section 9.05
Breach. Without otherwise limiting the remedies available to any Party, a breach by a Party or any of its Affiliates of any obligation under this Article IX shall not constitute a material breach under Section 7.06(iii) hereof.

  

 
 4
 
  


 * CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 








 Section 9.06 Lost Profits and Consequential Damages. In no event shall a Party be liable to
the other Party for lost profits or for any consequential damages that such other Party may suffer under or in connection with this Article IX. 
 Section 9.07 Consideration and Inducement. Each Party acknowledges and agrees that (i) each of the covenants of the Parties set forth in Sections 9.01 and 9.02 hereof has been agreed following extensive negotiations among
the Parties, (ii) the Parties have bargained for the benefit of such covenants in order to protect their investment in the Territory B Partnership, (iii) each of the covenants of the Parties set forth in Sections 9.01 and 9.02 hereof is an
essential element of the transactions contemplated by the Parties to protect their investment in the Territory B Partnership and (iv) it has independently consulted with its counsel and, after such consultation, agrees that the covenants set
forth in Sections 9.01 and 9.02 hereof are reasonable and proper. 
 Section 9.08 Deemed Amendment. The Parties’ covenants
contained in Sections 9.01 and 9.02 hereof with respect to the Business, specified time period and geographic area are separate and several. Each Party acknowledges that the limitations and restrictions set forth in Sections 9.01 and 9.02 hereof are
reasonable to protect the legitimate commercial interests of each of the Parties and their Affiliates, and in particular, to protect the investment in the Territory B Partnership, and that such covenants are given for valuable consideration and are
valid and enforceable against each Party, and each Party hereby waives all defenses (other than fraud and misrepresentation and other defenses similar thereto) to the maximum extent possible regarding the strict enforcement of such covenants. If any
court of competent jurisdiction determines that the definition of Business, the specified time period or the geographic area are unreasonable, arbitrary, too broad in description or scope, or against public policy, the shorter or smaller time period
or geographic area, or reduced scope of business, as the case may be, determined by such court to be reasonable, non-arbitrary, sufficiently narrow or not against public policy, may be enforced against each Party. Notwithstanding the foregoing, each
Party agrees to honor the provisions of Sections 9.01 and 9.02 hereof, including the definition of Business, the time period and the geographic area as specified herein and not to contest the enforceability of such definition of Business, time
period or geographic area. If any covenant or provision in this Article IX is determined to be void or unenforceable, in whole or in part, such determination shall not affect or impair, or be deemed to affect or impair, the validity or
enforceability of any other covenant or provision of this Article IX or of this Agreement. 
 6. Each Party shall cause its Affiliates that are parties to
any local agreements containing non-competition provisions inconsistent with or contrary to the provisions of this Amendment No. 1 to amend such local agreements to be in accordance with these provisions. 
 7. Except as explicitly amended hereby, other provisions of the Agreement (as otherwise amended, modified, supplemented or restated prior to the Effective Date) shall
remain unchanged. 
  

 
 5
 
  


 * CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 








 8. This Amendment No. 1 shall be governed by and construed in accordance with the laws of the State of New York
applicable to contracts executed and performed entirely in that state. 
 9. This Amendment No. 1 shall be effective as of the Effective Date,
notwithstanding its execution on the date hereof. 
  

 
 6
 
  


 * CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION 








 IN WITNESS WHEREOF, the Parties have duly executed this Amendment No. 1 to the Territory B Alliance
Support Agreement as of the day and year first written above. 
  

					
	SANOFI-SYNTHÉLABO
		
	By:	 	/s/ Jean-Pierre KERJOUAN
		 	Name:	 	Jean-Pierre KERJOUAN
		 	Title:	 	 Senior Vice President
 General
Counsel



  

					
	By:	 	/s/ Jean-Claude LEROY
		 	Name:	 	Jean-Claude LEROY
		 	Title:	 	 Senior Vice President
 Strategy and Business
Development



  

					
	BRISTOL-MYERS SQUIBB COMPANY
		
	By:	 	/s/ Richard J. Lane
		 	Name:	 	Richard J. Lane
		 	Title:	 	Executive Vice president



  


 * CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION